SNORD15A: A Potential Drug Target and Biomarker (G6079)

Target Name: SNORD15A

NCBI ID: G6079

SNORD15A

Other Name(s): small nucleolar RNA, C/D box 15A | RNU15A | SNORNA | U15A | Small nucleolar RNA, C/D box 15A

SNORD15A: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a class of non-coding RNA molecules that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the most well-known snRNAs is SNORD15A, a 24nt RNA molecule that is expressed in a variety of tissues and cells. While its function and potential clinical applications are still being explored, SNORD15A is an attractive drug target and biomarker due to its unique structure and gene expression patterns.

SNORD15A is characterized by its C/D box 15A region, which consists of 12nt of sequence and is responsible for binding to specific DNA sequences. This region is enriched in RNA-protein interactions and has been implicated in various cellular processes, including DNA replication, transcription, and splicing. Therefore, alterations in SNORD15A expression levels could have a significant impact on gene expression and cellular processes.

One of the key advantages of SNORD15A as a drug target is its expressedness in a variety of human tissues and cells. While many drug targets are difficult to study in human beings due to ethical concerns, the expression of SNORD15A across different cell types and tissues provides a unique opportunity to study its effects. Additionally, the use of RNA-based assays, such as RNA interference and RNA sequencing, allows researchers to quantify changes in SNORD15A expression levels and determine its efficacy as a drug.

SNORD15A has also been shown to play a role in various diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that SNORD15A is downregulated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that targeting SNORD15A may be a promising strategy for cancer treatment. Additionally, the expression of SNORD15A has been implicated in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, investigating the effects of drugs on SNORD15A expression levels may provide insights into the pathophysiology of these conditions and inform potential therapeutic approaches.

Another potential application of SNORD15A as a drug target is its role in the regulation of cellular processes that are altered in various diseases, such as neuropsychiatric disorders. For example, alterations in SNORD15A expression levels have been implicated in the regulation of synaptic plasticity, which is the ability of the nervous system to adapt and change over time. This suggests that SNORD15A may play a role in the development and treatment of neuropsychiatric disorders. Additionally, the use of drugs that specifically target SNORD15A may allow for more targeted and effective treatments of these disorders.

In addition to its potential clinical applications, SNORD15A also has the potential to serve as a biomarker for a variety of diseases. The expression of SNORD15A is known to be regulated by various factors, including DNA replication, transcription, and translation. Therefore, the levels of SNORD15A expression can be used as a marker for these processes and as a target for drugs that target these processes. For example, the use of RNA-based assays, such as qRT-PCR and western blotting, allows researchers to quantify changes in SNORD15A expression levels and determine its efficacy as a drug. Additionally, the use of biomarkers that specifically target SNORD15A may allow for more targeted and effective treatments of diseases associated with SNORD15A expression levels, such as neurodegenerative diseases.

In conclusion, SNORD15A is an attractive drug target and biomarker due to its unique structure and gene expression patterns. The expressedness of SNORD15A across different cell types and tissues makes it an

Protein Name: Small Nucleolar RNA, C/D Box 15A

The "SNORD15A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD15A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets